Navigation Links
Moving Beyond the Pill: Data Science to Impact Medicine More than the Drugs Themselves
Date:5/13/2013

TOKYO, May 13, 2013 /PRNewswire/ -- The global healthcare industry is in the middle of a massive remix, with disciplines merging and cross-pollinating.  Technology continues to intrude into biology and society, as boundaries shift and disappear.  Progressive healthcare business models are evolving to focus on personalization, communication, decentralization and collaboration.  To keep up, traditional care organizations must capture other areas of the value chain, as the patient becomes the central point of the system.

"The industrial revolution has arrived for the healthcare industry," said Frost & Sullivan Partner Reenita Das during her keynote presentation at the 12th International BIOtech Exhibition and Conference in Tokyo.  Das continued: "in the next 10 years, data science will have more to do with improving medicine than anything you will ever learn in medical school or anything currently being researched in the laboratory."

For a copy of her keynote presentation, Will Pharma Survive the Headwinds of Change in the New Healthcare Ecosystem, please email Anna Tsuji , Corporate Communications, at anna.tsuji@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country. 

Technology will play a large role in this healthcare evolution, as it shifts care outside of the hospital to the home and facilitates the use of data and analytics to better navigate patient wellness.  Electronic medical records (EMRs) and other data will be the foundation of disease databases, with analytics to develop protocols and appropriate pathways of treatment and diagnosis.  This will move the responsibility and control from individual clinicians to fully documented and approved standards – and more into the patients' hands.

"The consumer will take on the role of the CEO of their own health through increased engagement, access, and empowerment," said Das.  "This belief in the importance of collaboration is coming not only as the result of new technology and data sharing, but it also comes from a fundamental shift in understanding collaboration and the difference between drugs and science.  We must collaborate on science and compete on drugs."  

Additionally, the connectivity of IT solutions that support smaller and cheaper testing solutions will reduce dependence on large, expensive facilities to give individuals greater control over their health and wellness. This patient-centric health system opens the door to new market participants from industries such as retail, telecommunications, wellness/spa, as well as travel and tourism.

This will eventually facilitate customized service through individualized care plans based on one's needs and personal wishes – unique to the point of specificity to one's genomic variations. With this connectivity between users and providers, healthcare will ultimately become a collaborated effort where medical staff work together around the patient through coordinated team work, across disciplines.

The healthcare industry will also become more focused on preventing sickness rather than providing treatment. In 2012, the segment of global healthcare expenditure on treatment was 60 percent, which will significantly decrease to 35 percent by 2025.  This trend toward prevention over treatment after the fact will better support the world's elderly population of 60 years of age or older, which is anticipated to make up a quarter of the global population by 2025.  Additionally, 75 percent of those 60 years of age or older are anticipated to have at least one chronic condition.  By the time this population is 70 years old or more, 50 percent will have two or more chronic conditions. 

"We need to move beyond the pill to better plan for the future of healthcare," said Das. "Demographic changes are one of the biggest mega trends for healthcare, while convergence is the biggest driver of the industry's evolution, cross-pollinating ideas, technologies and applications."

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. 

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.  
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible.  This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.  

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?  

Contact Us:     Start the discussion
Join Us:               Join our community
Subscribe:       Newsletter on "the next big thing"
Register:        Gain access to visionary innovation

Contact:
Anna Tsuji
Corporate Communications – Japan
Tel: +81-(0)3-4550-2210
Email: anna.tsuji@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Over 50? Of Course Youve Still Got It, and the Y and Pfizer are Launching 50 MOVING FORWARD to Help You Keep It
2. Eighth Annual WLSA Convergence Summit Focuses on Moving from Innovation to Adoption
3. NW Bio Takes Next Steps In Moving Forward With Its Phase III Brain Cancer Trial In Europe
4. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
5. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
6. Home Access Health Corp. encourages cholesterol testing during American Heart Month, beyond
7. CVS Caremark Provides Strong Growth Outlook for 2013 and Beyond, Announces 38%Dividend Increase and Outlines Strategic Growth Framework
8. Beyond Lucid Technologies Receives Funding From Dalmore Investments
9. EORNA Spearheads Harmonisation of Nursing Education Standards Beyond Europe
10. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.
11. Canadas Sunnybrook Health Sciences Centre Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 ... ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron ... announced the signing of a three-year exclusive sales ... deploy a dedicated sales team to introduce Imprimis, ... primarily focused in 13 states in the U.S. ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... are expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) ... greater use of this type of healthcare model in the diagnosis and treatment ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 ... an educational and exciting 2-day program. , An attendee at a recent PAINWeekEnd ... approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL COMPASS To Navigate ... Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation of published author, ... the Board of Directors for CONTACT USA, and former member of the American Association ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... the development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic ... manufacture its ANCD BRAIN device as the product advances towards regulatory and clinical ...
Breaking Medicine News(10 mins):